Reconstruction of Jaw Bone Using Mesenchymal Stem Cells

This is an interventional treatment trial for Bone Atrophy focused on measuring Mesenchymal stem cells, bone augmentation, bone regeneration Read More

Inclusion Criteria:Patients presenting with an indication for an implant and wanting implant-borne prosthetic restoration.

• Patients presenting with lateral or vertical bone loss (focusing lateral bone loss) of the mandible behind the canine tooth.
• Lateral (width 5 mm or less) bone loss preventing the insertion of an implant without prior bone augmentation.
• Endentate for more than 6 months in the region requiring reconstruction.
• Endentate concerning at least 2 missing teeth in the region requiring reconstruction.
• Absence of clinical signs of infection in the region requiring reconstruction.
• Patients presenting with good dental hygiene (subjective criteria)
• Patients not presenting with any major oral pathologies.
• Dental crest size less than 5 mm.

General criteria:

• Adult patients over 18 and under 80 years of age.
• Patients in good general health presenting with a complete blood count and renal and hepatic function values within normal limits (confirmed by local laboratory tests).
• Patients with the capacity to understand medical information and give their informed consent.

Exclusion Criteria:

ocal criteria:

• Patients presenting with clinical or radiological signs of bone infection (acute or chronic osteomyelitis).
• Residual dentition close to the area requiring reconstruction with untreated endodontic disorder (apical granuloma or apical cyst).
• Untreated oral infection (cellulitis, periodontitis).
• Patients with poor hygiene (subjective criteria).
• Surgical procedure undertaken in the area requiring reconstruction less than 6 months prior to the bone graft.
• History of malignant tumors of the upper airways / digestive tract or of the jaw.
• History of or scheduled cervico-facial radiation therapy.

General criteria:

• The patient suffers from any serious coagulation disorders that could require substitution therapy
• The patient is receiving VKA therapy, which should be adjusted if necessary so that the INR does not exceed 2.5
• The patient has history of allergy to iodine or to local anesthetics(sulfites, etc.)., or a history of hematoma, or hemorrhage or blood coagulation disorders
• The patient has received localized iliac crest radiotherapy contraindicating withdrawal from the irradiated site
• The patient has major skin lesions or diseases.
• Patients presenting with bone metabolism disorders: hypophosphatemia, primary parathyroid osteitis or that is secondary to chronic renal insufficiency or osteomalacia, Paget's disease, vitamin D-related disorders, osteoporosis.
• Pregnant or breastfeeding women or women not using effective contraception if they are of childbearing age.
• Patients presenting with cancerous disorders (carcinoma, sarcoma, leukemia, lymphoma) or psychiatric disorders or with uncontrolled systemic diseases (diabetes, hypertension), or chronic renal disease.
• Severe bruxism.
• History of chemotherapy.
• Smoking or alcohol addiction. Occasional consumption of alcohol and/or smoking will be noted in the case report form.
• Patients with an ASA score of 0 or 1, incapable of tolerating general anesthesia.
• Immunosuppression
• Body mass index outside the normal range, particularly >30 because of increased surgical risk at the time of BM harvesting from the iliac crest.
• Risk of remote infection (orthopedic prosthesis implanted in the previous 6 months, patients presenting with a high risk of infective endocarditis, presence of pulmonary arteriovenous shunt, etc.).
• HIV, HTLV and/or syphilis seropositivity.
• Hepatitis B or C infection.
• Active autoimmune disease.
• History of immunosuppressant treatment or bone marrow treatment.
• Administration of treatment interfering with bone metabolism.
• Patients requiring antibiotic prophylaxis before any dental procedure
• Patients reticent to undergo dental care or periodontal treatment
• Concomitant treatments: history of treatment or current treatment with bisphosphonates, long term corticosteroid treatment.